nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

29.01.2021 | Original Article

The predictive value of body mass index on prognosis and adverse events of cancers treated with immunotherapy: a systematic review and meta-analysis

verfasst von: Yafei You, Chang Jiang, Kunwei Peng, Wenzhuo He, Lei Wang, Yanan Jin, Liangping Xia

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Objective

High body mass index (BMI) greater than 25 kg/m² has a complex relationship with cancers. The aim of this systematic review and meta-analysis is to explore controversy over whether BMI is correlated with outcomes including survival and immunotherapy-related adverse events (irAEs) in cancer patients treated with immunotherapy.

Methods

We searched PubMed, Embase, Web of Science, and The Cochrane Library for relevant studies published up to June 2020. Title/abstract screening, full-text review, data extraction, and quality assessment were performed independently. Subgroup analysis was based on sex, treatment lines, the status of programmed death-ligand 1 (PD-L1), and tumor types. Sensitivity analysis was performed by synthesizing studies that adjusted for certain covariates or studies with good quality. Statistical heterogeneity was evaluated by the I² value. Meta-analysis was performed with hazard ratio (HR) / odds ratio (OR) and 95% confidence intervals (CIs) as the effect measures.

Results

Twenty studies were included for survival and irAEs analyses. Patients with high BMI who underwent immunotherapy had longer overall survival (OS) (pooled hazard ratio, pHR = 0.71 [95% CI: 0.59–0.85]) and progression-free survival (PFS) (pHR = 0.76 [95% CI: 0.65–0.88]) than those with low BMI; at the same time, high-BMI patients had increased irAEs (OR = 2.54 [95% CI: 1.12–5.79]).

Conclusion

In general, high BMI was correlated with improved OS and PFS in patients treated with immunotherapy along with a high risk of irAEs. However, discrepant findings from subgroup analyses urgently call for further analysis.

Nur mit Berechtigung zugänglich

Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M (2018) Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol 6(6):e6–e15. https://doi.org/10.1016/s2213-8587(18)30150-5CrossRefPubMedPubMedCentral

Schoemaker MJ, Nichols HB, Wright LB, Brook MN, Jones ME, O’Brien KM, Adami HO, Baglietto L, Bernstein L, Bertrand KA, Boutron-Ruault MC, Braaten T, Chen Y, Connor AE, Dorronsoro M, Dossus L, Eliassen AH, Giles GG, Hankinson SE, Kaaks R, Key TJ, Kirsh VA, Kitahara CM, Koh WP, Larsson SC, Linet MS, Ma H, Masala G, Merritt MA, Milne RL, Overvad K, Ozasa K, Palmer JR, Peeters PH, Riboli E, Rohan TE, Sadakane A, Sund M, Tamimi RM, Trichopoulou A, Ursin G, Vatten L, Visvanathan K, Weiderpass E, Willett WC, Wolk A, Yuan JM, Zeleniuch-Jacquotte A, Sandler DP, Swerdlow AJ (2018) Association of body mass index and age with subsequent breast cancer risk in premenopausal women. JAMA Oncol 4(11):e181771. https://doi.org/10.1001/jamaoncol.2018.1771CrossRefPubMedPubMedCentral

Arnold M, Pandeya N, Byrnes G, Renehan PAG, Stevens GA, Ezzati PM, Ferlay J, Miranda JJ, Romieu I, Dikshit R, Forman D, Soerjomataram I (2015) Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol 16(1):36–46. https://doi.org/10.1016/s1470-2045(14)71123-4CrossRefPubMed

Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, Rha SY, Agarwal N, Yuasa T, Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DYC, Choueiri TK (2016) Body mass index and metastatic renal cell carcinoma: clinical and biological correlations. J Clin Oncol: Off J Am Soc Clin Oncol 34(30):3655–3663. https://doi.org/10.1200/jco.2016.66.7311CrossRef

Lennon H, Sperrin M, Badrick E, Renehan AG (2016) The obesity paradox in cancer: a review. Curr Oncol Rep 18(9):56. https://doi.org/10.1007/s11912-016-0539-4CrossRefPubMedPubMedCentral

Taghizadeh N, Boezen HM, Schouten JP, Schröder CP, Elisabeth de Vries EG, Vonk JM (2015) BMI and lifetime changes in BMI and cancer mortality risk. PLoS ONE 10(4):e0125261. https://doi.org/10.1371/journal.pone.0125261CrossRefPubMedPubMedCentral

McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA (2018) Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol 19(3):310–322. https://doi.org/10.1016/s1470-2045(18)30078-0CrossRefPubMedPubMedCentral

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. New Engl J Med 373(17):1627–1639. https://doi.org/10.1056/NEJMoa1507643CrossRefPubMed

Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. New Engl J Med 373(2):123–135. https://doi.org/10.1056/NEJMoa1504627CrossRefPubMed

10.

Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fargnoli MC, Ascierto PA, Ficorella C, Natoli C (2019) A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer 7(1):57. https://doi.org/10.1186/s40425-019-0527-yCrossRefPubMedPubMedCentral

11.

Kichenadasse G, Miners JO, Mangoni AA, Rowland A, Hopkins AM, Sorich MJ (2019) Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.5241CrossRefPubMedCentral

12.

Richtig G, Hoeller C, Wolf M, Wolf I, Rainer BM, Schulter G, Richtig M, Grubler MR, Gappmayer A, Haidn T, Kofler J, Huegel R, Lange-Asschenfeldt B, Pichler M, Pilz S, Heinemann A, Richtig E (2018) Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi-centre study. PLoS ONE 13(10):e0204729. https://doi.org/10.1371/journal.pone.0204729CrossRefPubMedPubMedCentral

13.

Xu H, Cao D, He A, Ge W (2019) The prognostic role of obesity is independent of sex in cancer patients treated with immune checkpoint inhibitors: a pooled analysis of 4090 cancer patients. Int Immunopharmacol 74:105745. https://doi.org/10.1016/j.intimp.2019.105745CrossRefPubMed

14.

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097CrossRefPubMedPubMedCentral

15.

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. https://doi.org/10.1007/s10654-010-9491-zCrossRefPubMed

16.

Gomes JR (2017) Analysis of the impact of body mass index in the treatment of metastatic melanoma with ipilimumab. J Clin Oncol 35(15_suppl):e21044CrossRef

17.

Zhi J, Khozin S, Kuk D, Torres A, Sorg R, Lee S, Miksad R, Pazdur R, Abernethy A (2018) Association of baseline body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with nivolumab (N) and pembrolizumab (P). J Clin Oncol 36:6553–6553. https://doi.org/10.1200/JCO.2018.36.15_suppl.6553CrossRef

18.

Labomascus S, Fughhi I, Bonomi P, McDonald A, Batus M, Fidler MJ, Basu S, Borgia J (2018) P2.01–61 Body mass index over time is associated with overall survival in advanced NSCLC patients treated with immunotherapy. J Thorac Oncol. https://doi.org/10.1016/j.jtho.2018.08.1115CrossRef

19.

Dumenil C, Massiani MA, Dumoulin J, Giraud V, Labrune S, Chinet T, Giroux Leprieur E (2018) Clinical factors associated with early progression and grade 3–4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. PLoS ONE 13(4):e0195945. https://doi.org/10.1371/journal.pone.0195945CrossRefPubMedPubMedCentral

20.

Dizman N, Bergerot P, Bergerot CD, Philip EJ, Salgia MM, Hsu J, Adashek J, Pal SK (2018) 894PComparative effect of body-mass index on outcome with targeted therapy and immunotherapy in patients with metastatic renal cell carcinoma (mRCC). Ann Oncol. https://doi.org/10.1093/annonc/mdy283.103CrossRef

21.

Ibrahimi S, Mukherjee S, Roman D, King C, Machiorlatti M, Aljumaily R (2018) Effect of body mass index and albumin level on outcomes of patients receiving anti PD-1/PD-L1 therapy. J Clin Oncol 36:213–213. https://doi.org/10.1200/JCO.2018.36.5_suppl.213CrossRef

22.

Lalani A-K, Xie W, Flippot R, Steinharter J, Harshman L, McGregor B, Heng D, Choueiri T (2019) Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 37:566–566. https://doi.org/10.1200/JCO.2019.37.7_suppl.566CrossRef

23.

Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, Grossenbacher SK, Withers SS, Rebhun RB, Hartigan-O’Connor DJ, Mendez-Lagares G, Tarantal AF, Isseroff RR, Griffith TS, Schalper KA, Merleev A, Saha A, Maverakis E, Kelly K, Aljumaily R, Ibrahimi S, Mukherjee S, Machiorlatti M, Vesely SK, Longo DL, Blazar BR, Canter RJ, Murphy WJ, Monjazeb AM (2019) Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med 25(1):141–151. https://doi.org/10.1038/s41591-018-0221-5CrossRefPubMed

24.

Kondo T, Nomura M, Otsuka A, Nonomura Y, Kaku Y, Matsumoto S, Muto M (2019) Predicting marker for early progression in unresectable melanoma treated with nivolumab. Int J Clin Oncol 24(3):323–327. https://doi.org/10.1007/s10147-018-1345-9CrossRefPubMed

25.

Taniguchi Y, Tamiya A, Isa S-I, Nakahama K, Okishio K, Shiroyama T, Suzuki H, Inoue T, Tamiya M, Hirashima T, Imamura F, Atagi S (2017) Predictive factors for poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab. Anticancer Res 37(10):5857–5862PubMed

26.

Shiroyama T, Suzuki H, Tamiya M, Tamiya A, Tanaka A, Okamoto N, Nakahama K, Taniguchi Y, Isa SI, Inoue T, Imamura F, Atagi S, Hirashima T (2018) Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. Cancer Med 7(1):13–20. https://doi.org/10.1002/cam4.1234CrossRefPubMed

27.

Bergerot PG, Bergerot CD, Philip EJ, Meza L, Dizman N, Hsu J, Pal SK (2019) Targeted therapy and immunotherapy: effect of body mass index on clinical outcomes in patients diagnosed with metastatic renal cell carcinoma. Kidney Cancer 3(1):63–70. https://doi.org/10.3233/kca-180047CrossRef

28.

Ichihara E, Harada D, Inoue K, Sato K, Hosokawa S, Kishino D, Watanabe K, Ochi N, Oda N, Hara N, Hotta K, Maeda Y, Kiura K (2020) The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands) 139:140–145. https://doi.org/10.1016/j.lungcan.2019.11.011CrossRef

29.

Sanchez A, Furberg H, Kuo F, Vuong L, Ged Y, Patil S, Ostrovnaya I, Petruzella S, Reising A, Patel P, Mano R, Coleman J, Russo P, Liu CH, Dannenberg AJ, Chan TA, Motzer R, Voss MH, Hakimi AA (2020) Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. Lancet Oncol 21(2):283–293. https://doi.org/10.1016/s1470-2045(19)30797-1CrossRefPubMed

30.

Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, Marconcini R, Russano M, Zeppola T, Anesi C, Filetti M, Marchetti P, Botticelli A, Gelibter A, De Galitiis F, Vitale MG, Rastelli F, Tudini M, Silva RR, Atzori F, Chiari R, Ricciuti B, De Giglio A, Migliorino MR, Mallardo D, Vanella V, Mosillo C, Bracarda S, Rinaldi S, Berardi R, Natoli C, Ficorella C, Porzio G, Ascierto PA (2020) Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of immune-related adverse events. Eur J Cancer (Oxford, England: 1990) 128:17–26. https://doi.org/10.1016/j.ejca.2019.12.031CrossRef

31.

Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Huillard O, Boudou-Rouquette P, Chanal J, Arrondeau J, Franck N, Alexandre J, Blanchet B, Leroy K, Avril M-F, Dupin N, Aractingi S (2017) Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Invest New Drugs 35(4):436–441. https://doi.org/10.1007/s10637-017-0464-xCrossRefPubMed

32.

Escoin-Perez C, Blasco S, Juan-Vidal O (2020) Immune checkpoint inhibitors in special populations. a focus on advanced lung cancer patients. Lung Cancer (Amsterdam, Netherlands) 144:1–9. https://doi.org/10.1016/j.lungcan.2020.03.026CrossRef

33.

Passaro A, Spitaleri G, Gyawali B, de Marinis F (2019) Immunotherapy in non-small-cell lung cancer patients with performance status 2: clinical decision making with scant evidence. J Clin Oncol 37(22):1863–1867. https://doi.org/10.1200/jco.18.02118CrossRefPubMed

34.

Azvolinsky A (2014) Cancer prognosis: role of BMI and fat tissue. J Natl Cancer Inst 106(6):dju177. https://doi.org/10.1093/jnci/dju177CrossRefPubMed

35.

Masel EK, Berghoff AS, Füreder LM, Heicappell P, Schlieter F, Widhalm G, Gatterbauer B, Dieckmann U, Birner P, Bartsch R, Schur S, Watzke HH, Zielinski CC, Preusser M (2017) Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: a retrospective analysis of 624 patients. Eur J Cancer Care (Engl). https://doi.org/10.1111/ecc.12707CrossRef

36.

Yap WK, Shih MC, Kuo C, Pai PC, Chou WC, Chang KP, Tsai MH, Tsang NM (2018) Development and validation of a nomogram for assessing survival in patients with metastatic lung cancer referred for radiotherapy for bone metastases. JAMA Netw Open 1(6):e183242. https://doi.org/10.1001/jamanetworkopen.2018.3242CrossRefPubMedPubMedCentral

37.

Sepesi B, Gold KA, Correa AM, Heymach JV, Vaporciyan AA, Roszik J, Dmitrovsky E, Liu X (2017) The influence of body mass index on overall survival following surgical resection of non-small cell lung cancer. J Thorac Oncol 12(8):1280–1287. https://doi.org/10.1016/j.jtho.2017.05.010CrossRefPubMedPubMedCentral

38.

Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA (2016) Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol: Off J Am Soc Clin Oncol 34(35):4270–4276CrossRef

39.

Invitti C (2002) Obesity and low-grade systemic inflammation. Minerva Endocrinol 27(3):209–214PubMed

40.

Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ (2013) Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res: An Off J Am Assoc Cancer Res 19(22):6074–6083. https://doi.org/10.1158/1078-0432.CCR-12-2603CrossRef

41.

Murphy KA, James BR, Sjaastad FV, Kucaba TA, Kim H, Brincks EL, Chua SC Jr, Wilber A, Griffith TS (2018) Cutting edge: elevated leptin during diet-induced obesity reduces the efficacy of tumor immunotherapy. J Immunol (Baltimore, Md: 1950) 201(7):1837–1841. https://doi.org/10.4049/jimmunol.1701738CrossRef

42.

Naylor C, Petri WA (2016) Leptin regulation of immune responses. Trends Mol Med 22(2):88–98. https://doi.org/10.1016/j.molmed.2015.12.001CrossRefPubMed

43.

Saucillo DC, Gerriets VA, Sheng J, Rathmell JC, Maciver NJ (2014) Leptin metabolically licenses T cells for activation to link nutrition and immunity. J Immunol (Baltimore, Md: 1950) 192(1):136–144. https://doi.org/10.4049/jimmunol.1301158CrossRef

44.

Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science (New York, NY) 350(6264):1079–1084. https://doi.org/10.1126/science.aad1329CrossRef

45.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science (New York, NY) 359(6371):91–97. https://doi.org/10.1126/science.aan3706CrossRef

46.

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (New York, NY) 359(6371):97–103. https://doi.org/10.1126/science.aan4236CrossRef

47.

Mirsoian A, Murphy WJ (2015) Obesity and cancer immunotherapy toxicity. Immunotherapy 7(4):319–322. https://doi.org/10.2217/imt.15.12CrossRefPubMed

48.

Berg AH, Scherer PE (2005) Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96(9):939–949. https://doi.org/10.1161/01.Res.0000163635.62927.34CrossRefPubMed

49.

Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, Gelber RD, Goldhirsch A (2018) Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol 19(6):737–746. https://doi.org/10.1016/s1470-2045(18)30261-4CrossRefPubMed

50.

Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science (New York, NY) 331(6024):1565–1570. https://doi.org/10.1126/science.1203486CrossRef

51.

Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol: Off J Eur Soc Med Oncol 28(2):368–376. https://doi.org/10.1093/annonc/mdw443CrossRef

52.

Schneider G, Kirschner MA, Berkowitz R, Ertel NH (1979) Increased estrogen production in obese men. J Clin Endocrinol Metab 48(4):633–638. https://doi.org/10.1210/jcem-48-4-633CrossRefPubMed

53.

Kyrgiou M, Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, Martin-Hirsch P, Tsilidis KK (2017) Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ 356:j477. https://doi.org/10.1136/bmj.j477CrossRefPubMedPubMedCentral

54.

Park Y, Colditz GA (2017) Fresh evidence links adiposity with multiple cancers. BMJ 356:j908. https://doi.org/10.1136/bmj.j908CrossRefPubMed

Titel: The predictive value of body mass index on prognosis and adverse events of cancers treated with immunotherapy: a systematic review and meta-analysis
verfasst von: Yafei You
Chang Jiang
Kunwei Peng
Wenzhuo He
Lei Wang
Yanan Jin
Liangping Xia
Publikationsdatum: 29.01.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 8/2021
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-021-02858-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

The predictive value of body mass index on prognosis and adverse events of cancers treated with immunotherapy: a systematic review and meta-analysis

Abstract

Objective

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2021

LncRNA UCA1 attenuated the killing effect of cytotoxic CD8 + T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway

Immunotherapy response modeling by ex-vivo organ culture for lung cancer

Correction to: Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti‑B7H3 immunotherapy

Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors

Pembrolizumab-induced immune-mediated fatal colitis with concurrent giardia infection

Correction to: Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie